PanGen Biotech Inc Market Cap ($37.49 Million)
Market Cap & Net Worth: PanGen Biotech Inc (222110)
PanGen Biotech Inc market cap. PanGen Biotech Inc (KQ:222110) has a market capitalization of $37.49 Million (₩55.33 Billion) as of November 5, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #22756 globally and #1497 in its home market, demonstrating a -10.48% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying PanGen Biotech Inc's stock price ₩4100.00 by its total outstanding shares 13494197 (13.49 Million). Also see cash efficiency ratio of PanGen Biotech Inc for how efficiently the company converts equity into cash flow.
PanGen Biotech Inc Market Cap History (2016–2026)
PanGen Biotech Inc market cap history from 2016 to 2026. Data shows change from $152.26 Million to $37.49 Million (-14.69% CAGR). Check PanGen Biotech Inc (222110) stock price for real-time trading data and today's change.
Index Memberships
PanGen Biotech Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$207.23 Billion | 0.02% | #733 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$207.23 Billion | 0.02% | #733 of 1384 |
Weight: PanGen Biotech Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
PanGen Biotech Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how PanGen Biotech Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of PanGen Biotech Inc to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.00x
PanGen Biotech Inc's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.06x
PanGen Biotech Inc's market cap is 0.06 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $152.26 Million | $1.46 Billion | -$5.13 Billion | 0.10x | N/A |
| 2017 | $135.34 Million | $2.37 Billion | -$7.02 Billion | 0.06x | N/A |
| 2018 | $96.02 Million | $5.68 Billion | -$4.63 Billion | 0.02x | N/A |
| 2019 | $71.06 Million | $2.88 Billion | -$8.94 Billion | 0.02x | N/A |
| 2020 | $92.82 Million | $6.19 Billion | -$4.36 Billion | 0.01x | N/A |
| 2021 | $85.50 Million | $7.94 Billion | -$3.31 Billion | 0.01x | N/A |
| 2022 | $59.44 Million | $6.50 Billion | -$4.49 Billion | 0.01x | N/A |
| 2023 | $62.92 Million | $7.32 Billion | -$4.49 Billion | 0.01x | N/A |
| 2024 | $52.13 Million | $14.67 Billion | $943.69 Million | 0.00x | 0.06x |
Competitor Companies of 222110 by Market Capitalization
Companies near PanGen Biotech Inc in the global market cap rankings as of November 5, 2026. Also see 222110 current and non-current assets for a full breakdown of the balance sheet.
Key companies related to PanGen Biotech Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of PanGen Biotech Inc (2016–2026)
Market capitalization of PanGen Biotech Inc from 2016 to today. Between 2016 and today, PanGen Biotech Inc's market cap moved from $152.26 Million to $ 37.49 Million, with a yearly change of -14.69%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩37.49 Million | -26.79% |
| 2025 | ₩51.21 Million | -1.75% |
| 2024 | ₩52.13 Million | -17.15% |
| 2023 | ₩62.92 Million | +5.85% |
| 2022 | ₩59.44 Million | -30.48% |
| 2021 | ₩85.50 Million | -7.88% |
| 2020 | ₩92.82 Million | +30.63% |
| 2019 | ₩71.06 Million | -26.00% |
| 2018 | ₩96.02 Million | -29.05% |
| 2017 | ₩135.34 Million | -11.11% |
| 2016 | ₩152.26 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of PanGen Biotech Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $37.49 Million USD |
| MoneyControl | $37.49 Million USD |
| MarketWatch | $37.49 Million USD |
| marketcap.company | $37.49 Million USD |
| Reuters | $37.49 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About PanGen Biotech Inc
PanGen Biotech Inc. operates as a biologics company in South Korea. It develops biosimilar products, such as EPO, recombinant factor VIII, G-CSF, etc. The company also provides CHO cell lines for proteins and monoclonal antibodies; and one-stop services ranging from producer cell line development to GMP production. In addition, it offers reagents, quantitation kits, and cell based assay systems, … Read more